Antidepressant Vortioxetine shows potential in treating glioblastomas when combined with standard treatments, based on a Nature study.

Vortioxetine, an approved antidepressant, has shown unexpected promise in treating glioblastomas—aggressive brain tumors with a survival rate of just 12-18 months—according to a study in Nature. When combined with standard treatments like surgery and chemotherapy, it demonstrated good efficacy. While vortioxetine is safe and cost-effective, clinical trials are needed to determine proper dosages and effectiveness in humans, and self-medication is not recommended.

September 20, 2024
21 Articles